




Sector Risk Rating



What to Watch?

- Recurring high level of M&A activity aimed at bolstering big pharma's pipelines as a more efficient alternative to internal R&D investments
- Competition from generic and biosimilar drugs eating away at patented drugs market shares
- Continuous rise in the number of new drug launches in 2018
- Negative regulatory fallout from drug price gouging in the US


Never mind Uncle Sam and pop prescription pills

The global prescription drug market grew a little (+0.8%) in 2017 vs. 2016 due to the depreciation of the USD against most of other currencies, especially Asian ones, as the US is the largest outlet for foreign medicines with a world market share of 33%. All drug makers have to cope with governments' tightening cost controls over drug price fixing as it is one way to keep new medicines affordable for patients in spite of their growing criticism about too expensive health prices have become recently.

Even if the rise in cheaper generic drugs sales helps ease the financial burden of public social security schemes, drug makers continue to cash in on their pricing power of bringing innovative drugs onto market to keep up pharmaceuticals in its bullish momentum. So political rhetoric on drug price gouging is likely to swell in 2018, especially in the US where the skyrocketing price of the Daraprim drug (by 5,000% overnight) caused a public outcry two years ago.

Patients often want the most recent medicines from their physicians. It usually means that these latter are likely to prescribe the most expensive ones. So the upswing of 70% in the number of new drug launches in the US in 2017 (vs. 2016) should bolster drug sales in 2018. We expect the growth rate of global prescription drug sales to be around +5% over the ongoing year as a result.

Worldwide prescription drug sales
(Denominated in billions of USD)




Sources: Evaluate Pharma, Euler Hermes

Sector Value:
1,100bn
USD

Key Players

Country	Role	Sector Risk
United States	#1 producer #1 importer	●
Switzerland	#3 producer	●
China	#2 producer	●

ID Card



Strengths

- Structural rise in demand boosted by growing middle classes in emerging markets and ageing population as a whole
- Resilience of drug spending irrespectively of economic cycle
- Increasing R&D costs well covered by strong cash generation

Weaknesses

- All EU public health insurance systems putting downward pressures on (not enough) innovative drug price levels
- Drug pricing issues, especially across the US, tarnishing the whole pharmaceutical industry's reputation
- Strict healthcare laws and regulations


Subsectors Insights

Prescription branded drugs: Patents expiration put a part of their sales at risk as competitors can manufacture them at lower cost

Generics: Market growth potential stemming from patent expiries of branded drugs. Parallel rise in biosimilar sales corresponding to branded biotechnological drugs going off patent

OTC: Non-prescription drugs whose growth rate has been lagging behind recently

Recent Sector Risk Changes



DISCLAIMER

These assessments are, as always, subject to the disclaimer provided below.

This material is published by Euler Hermes SA, a Company of Allianz, for information purposes only and should not be regarded as providing any specific advice. Recipients should make their own independent evaluation of this information and no action should be taken, solely relying on it. This material should not be reproduced or disclosed without our consent. It is not intended for distribution in any jurisdiction in which this would be prohibited. Whilst this information is believed to be reliable, it has not been independently verified by Euler Hermes and Euler Hermes makes no representation or warranty (express or implied) of any kind, as regards the accuracy or completeness of this information, nor does it accept any responsibility or liability for any loss or damage arising in any way from any use made of or reliance placed on, this information. Unless otherwise stated, any views, forecasts, or estimates are solely those of the Euler Hermes Economics Department, as of this date and are subject to change without notice. Euler Hermes SA is authorised and regulated by the Financial Markets Authority of France.

© Copyright 2018 Euler Hermes. All rights reserved.